INCY Stock Recent News
INCY LATEST HEADLINES
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Furthers Commitment to People Living with Atopic Dermatitis by Sharing Additional Patient Experiences as part of its Moments of Clarity Program.
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, October 29, 2024. The schedule for the press release and conference call/webcast is as follows: • Q3 2024 Press Release: October 29, 2024 at 7:00 a.m. ET • Q3 2024 Conference Call: October 29, 2024 at 8:00 a.m. ET • Domestic Dial-In Number: 877-407-3042 • International Dial-In Number: 201-389-0864 • Conference.
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).
Though INCY's performance in the year so far has been good, increasing competition for Jakafi is a concern. We advise investors to wait and watch before turning positive.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Multiple Late-Breaking Data Presentations from Incyte's Dermatology Portfolio will be Featured at the EADV 2024 Congress.
– Trial met its primary endpoint across all dose cohorts with 74% of patients at the 0.3 mg/kg every 2 weeks dose achieving a complete or partial response within the first six months of treatment – – Niktimvo approved by U.S. FDA for the treatment of chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg – – Niktimvo added to latest NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the treatment of chronic GVHD – WILMINGTON, Del. and WALTHAM, Mass.
Truist Securities has downgraded Incyte Corporation INCY, noting Jakafi's (ruxolitinib) patent loss approaching in 2028.
INCY's INCB123667 data show the candidate's potential as a differentiated treatment option for cancers with increased cyclin E1 activity, amplification and/or overexpression in cells predictive of CDK2 dependency.
DOHA, Qatar--(BUSINESS WIRE)--Doğuş Technology, one of Turkey's leading tech companies, will showcase its innovative, technology-driven solutions for the construction industry at ConteQ Expo 2024, alongside Doğuş Construction, at the Qatar National Convention Center from September 16-18. Both companies will present their projects that drive sector transformation by enhancing efficiency and sustainability in construction by integrating engineering and technology. Innovative and Sustainable Proje.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte's CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer.